Phase II Trial of Panzem for Renal Cell Carcinoma Initiated
EntreMed has initiated a phase II trial of its drug candidate Panzem (2-methoxyestradiol) in patients with metastatic renal cell carcinoma who have failed treatment with or are progressing while being treated with sunitinib (Sutent).
ROCKVILLE, MarylandEntreMed has initiated a phase II trial of its drug candidate Panzem (2-methoxyestradiol) in patients with metastatic renal cell carcinoma who have failed treatment with or are progressing while being treated with sunitinib (Sutent). Glenn Liu, MD, University of Wisconsin, is the principal investigator. Panzem will be tested alone and in combination with suni-tinib. It has been hypothesized that a mechanism for tyrosine kinase inhibitor failure is a compensatory increase in HIF-1?. Panzem inhibits HIF-1? and thus could restore tumor response to sunitinib. For more in-formation about the trial, call 800-622-8922.
